Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Protein DUSP4 prevents immune cell exhaustion in colorectal cancer (opens in a new tab)

news-medical.net · 2026-11-04

Short answerEvidenceSource

Short answer

Mostly not supported

Mostly not supported.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 1 supported
  • 4 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mostly not supported

The one claim we could check holds up. One of five claims matches the study. This overall rating is based only on the claims we could check. Four claims the study doesn't address.

  • 1 supported
  • 4 not covered
Open claim evidence
3
Source paper

Source layer

The 2 papers the story cites

Source study separated from background citations.

The research anchor for the report.

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5Not coveredWhen DUSP4 was absent, CD8+ T cells became less effective, showed more signs of exhaustion, and laboratory models developed a greater colorectal tumor burden.View evidenceHide evidence

Why this verdict

The abstract supports that global DUSP4 deficiency in an AOM/DSS male mouse CRC model increases tumorigenesis and compromises CD8+ T cell–mediated anti-tumor immunity. However, the specific claim that CD8+ T cells showed more signs of exhaustion is not present in the abstract-level profile, and details on tumor-burden metrics are not available at this depth.

1

Study evidence

Global loss of DUSP4 increases tumorigenesis and impairs CD8+ T cell–mediated anti-tumor immunity in AOM/DSS-induced colorectal cancer in male mice (abstract).

“in AOM/DSS-induced male mouse CRC models, global DUSP4 deficiency enhances tumorigenesis and compromises CD8+ T cell-mediated anti-tumor immunity.”
Claim 2 of 5Not coveredIn laboratory models, increasing DUSP4 activity helped CAR-T cells multiply more readily and kill colorectal cancer cells more effectively, and treatment with these cells produced smaller and lighter tumors than standard CAR-T cells.View evidenceHide evidence

Why this verdict

The abstract supports the core finding that CRISPRa-mediated DUSP4 activation promotes anti-CD19 CAR-T proliferation and anti-tumor cytotoxicity/efficacy in a CD19+ CRC xenograft mouse model. But the more specific statements that tumors were smaller and lighter than with standard CAR-T cells, and the exact comparator details, are not reported in the abstract-level profile.

1

Study evidence

CRISPRa-mediated activation of DUSP4 in anti-CD19 CAR-T cells promotes CAR-T cell proliferation and anti-tumor cytotoxicity in a CD19+ colorectal cancer xenograft mouse model (abstract claim).

“In a CD19+ CRC xenograft mouse model, CRISPRa-mediated DUSP4 activation promotes anti-CD19 CAR-T cell proliferation and anti-tumor cytotoxicity.”
Claim 3 of 5Not coveredTumor tissue from 105 colorectal cancer patients showed that lower DUSP4 levels were associated with poorer overall survival, with a similar trend in an independent dataset.View evidenceHide evidence

As stated105 patients

Why this verdict

The abstract supports the associational direction: lower DUSP4 expression in CRC tissue is associated with shorter survival. However, the abstract-level profile does not provide the stated sample size of 105 patients, specify overall survival, identify an independent dataset, or report statistical details, so those parts are not verifiable at abstract depth.

1

Study evidence

Lower DUSP4 expression across CRC tumor tissue is associated with shorter patient survival (abstract statement).

“Patients with colorectal cancers (CRC) with lower DUSP4 expression across the CRC tissue exhibit shorter survival compared to those with higher DUSP4 expression.”
Claim 4 of 5Not coveredThe researchers said the CAR-T findings remain preclinical, and that the colorectal cancer cells used in the CAR-T model were engineered to carry CD19, the target recognized by the CAR-T cells.View evidenceHide evidence

Why this verdict

The paper profile supports that the CAR-T work is preclinical and performed in a CD19+ CRC xenograft mouse model using anti-CD19 CAR-T cells. But the abstract-level profile does not explicitly state that the CRC cells were engineered to carry CD19, so that caveat is plausible but not verifiable at this depth.

1

Study evidence

CRISPRa-mediated activation of DUSP4 in anti-CD19 CAR-T cells promotes CAR-T cell proliferation and anti-tumor cytotoxicity in a CD19+ colorectal cancer xenograft mouse model (abstract claim).

“In a CD19+ CRC xenograft mouse model, CRISPRa-mediated DUSP4 activation promotes anti-CD19 CAR-T cell proliferation and anti-tumor cytotoxicity.”
Claim 5 of 5SupportedResearchers identified DUSP4 as a protein that helps CD8+ T cells maintain their anti-tumor function in colorectal cancer.View evidenceHide evidence

Why this verdict

The abstract supports the central framing that DUSP4 helps sustain CD8+ T-cell anti-tumor function in colorectal cancer models: DUSP4 deficiency compromises CD8+ T cell–mediated anti-tumor immunity, and DUSP4 activation improves CAR-T function. The headline-level causal wording is acceptable only in the preclinical/mechanistic sense supported by the abstract, not as a demonstrated causal effect in human CRC patients.

1

Study evidence

Global loss of DUSP4 increases tumorigenesis and impairs CD8+ T cell–mediated anti-tumor immunity in AOM/DSS-induced colorectal cancer in male mice (abstract).

“in AOM/DSS-induced male mouse CRC models, global DUSP4 deficiency enhances tumorigenesis and compromises CD8+ T cell-mediated anti-tumor immunity.”
2

Study evidence

DUSP4 knockout increases ERK2-mediated Klf2 expression in CD8+ T cells, and this is associated with suppression of KLF2-mediated cytotoxic programs.

“Mechanistically, DUSP4 knockout increases ERK2-mediated expression of the T cell activation regulator Klf2, thereby suppressing KLF2-mediated cytotoxic programs.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Mechanistic pathway: DUSP4 knockout increases ERK2-mediated Klf2 expression, suppressing KLF2-mediated cytotoxic programs in CD8+ T cells.

    The story reports the functional role of DUSP4 in CD8+ T cells but does not mention the ERK2–Klf2 mechanistic axis, which is a primary mechanistic contribution in the paper profile.

    From in vitro / ex vivo CD8+ T cell mechanistic assays

4 things the story did carry across
  • DUSP4 deficiency increases tumorigenesis and compromises CD8+ T cell–mediated anti-tumor immunity in an AOM/DSS-induced male mouse CRC model.
  • CRISPRa-mediated DUSP4 activation enhances anti-CD19 CAR-T proliferation and anti-tumor efficacy/cytotoxicity in a CD19+ CRC xenograft mouse model.
  • Lower DUSP4 expression in human CRC tissue is associated with shorter patient survival.
  • The CAR-T evidence is preclinical and uses a CD19+ CRC xenograft/anti-CD19 CAR-T system, limiting direct relevance to native CRC antigens or clinical CRC treatment.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

4

Evidence read

study summary

Lead result

in vivo animal

1Lead resultin vivo animalIn an AOM/DSS-induced mouse colorectal cancer model, DUSP4 deficiency increases tumorigenesis and impairs CD8+ T cell–mediated anti-tumor immunity.in vivo animal: AOM/DSS chemical induction of CRC in male mice; global Dusp4 knockoutExpand

In plain English

In AOM/DSS-induced male mouse colorectal cancer models, global DUSP4 (Dusp4) deficiency increases tumorigenesis and compromises CD8+ T cell–mediated anti-tumor immunity, as reported in the paper abstract.

Key findings

  • Global loss of DUSP4 increases tumorigenesis and impairs CD8+ T cell–mediated anti-tumor immunity in AOM/DSS-induced colorectal cancer in male mice (abstract).
“in AOM/DSS-induced male mouse CRC models, global DUSP4 deficiency enhances tumorigenesis and compromises CD8+ T cell-mediated anti-tumor immunity.”
What this piece can’t prove
  • Global knockout design leaves open whether observed immune effects are T cell–intrinsic or secondary to other cell types or tumor-intrinsic changes; abstract does not provide cell-type–specific evidence.

2 further details could not be confirmed from the summary.

2secondary dataDUSP4 expression in human colorectal cancer is associated with patient survival (lower DUSP4 across CRC tissue correlates with shorter survival).secondary data survival association (tumor expression stratification and survival analysis)Expand

In plain English

In human colorectal cancer (CRC) samples, lower tumor DUSP4 expression is reported to be associated with shorter patient survival (statement from abstract); quantitative details and dataset source are not provided in the abstract.

Key findings

  • Lower DUSP4 expression across CRC tumor tissue is associated with shorter patient survival (abstract statement).
“Patients with colorectal cancers (CRC) with lower DUSP4 expression across the CRC tissue exhibit shorter survival compared to those with higher DUSP4 expression.”
What this piece can’t prove
  • Abstract-only reporting: no dataset identifiers, sample size, or statistical details.
  • Unspecified expression measurement method and cutoff for low vs high DUSP4.
  • Unclear whether analyses adjusted for potential confounders (tumor stage, treatment, etc.).
  • Observational association; causality not established.
3in vitroMechanism: DUSP4 knockout increases ERK2-mediated Klf2 expression, suppressing KLF2-driven cytotoxic programs in CD8+ T cells.in vitro / ex vivo CD8+ T cell mechanistic assaysExpand

In plain English

The paper reports that loss of DUSP4 increases ERK2-mediated expression of the transcription factor Klf2 in CD8+ T cells, which in turn suppresses KLF2-driven cytotoxic gene programs, linking DUSP4 to a signaling/transcriptional axis that supports CD8+ T cell effector function.

Key findings

  • DUSP4 knockout increases ERK2-mediated Klf2 expression in CD8+ T cells, and this is associated with suppression of KLF2-mediated cytotoxic programs.
“Mechanistically, DUSP4 knockout increases ERK2-mediated expression of the T cell activation regulator Klf2, thereby suppressing KLF2-mediated cytotoxic programs.”
What this piece can’t prove
  • Unclear whether mechanistic experiments used human or mouse CD8+ T cells or the specific cellular context (primary cells vs. cell lines).

2 further details could not be confirmed from the summary.

4in vivo animalTherapeutic proof-of-concept: CRISPRa-mediated DUSP4 activation enhances anti-CD19 CAR-T proliferation and anti-tumor efficacy in a CRC xenograft mouse model.In vivo CD19+ CRC xenograft; anti-CD19 CAR-T cells with CRISPRa-mediated DUSP4 activationExpand

In plain English

In a CD19+ colorectal cancer xenograft mouse model, CRISPRa-mediated activation of DUSP4 in anti-CD19 CAR-T cells increased CAR-T proliferation and enhanced anti-tumor cytotoxicity/efficacy (abstract statement).

Key findings

  • CRISPRa-mediated activation of DUSP4 in anti-CD19 CAR-T cells promotes CAR-T cell proliferation and anti-tumor cytotoxicity in a CD19+ colorectal cancer xenograft mouse model (abstract claim).
“In a CD19+ CRC xenograft mouse model, CRISPRa-mediated DUSP4 activation promotes anti-CD19 CAR-T cell proliferation and anti-tumor cytotoxicity.”
What this piece can’t prove
  • Abstract does not report safety, persistence, or long-term outcome measures for the modified CAR-T cells.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 40 candidate papers

And 34 more candidates considered.